Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OXGN's Cash to Debt is ranked higher than
82% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. OXGN: No Debt )
OXGN' s 10-Year Cash to Debt Range
Min: 23.3   Max: No Debt
Current: No Debt

Interest Coverage No Debt
OXGN's Interest Coverage is ranked higher than
61% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OXGN: No Debt )
OXGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.05
M-Score: -3.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12738.95
OXGN's Operating margin (%) is ranked higher than
50% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. OXGN: -12738.95 )
OXGN' s 10-Year Operating margin (%) Range
Min: -1304800   Max: -35.75
Current: -12738.95

-1304800
-35.75
Net-margin (%) -12743.16
OXGN's Net-margin (%) is ranked higher than
50% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. OXGN: -12743.16 )
OXGN' s 10-Year Net-margin (%) Range
Min: -1190900   Max: -41.98
Current: -12743.16

-1190900
-41.98
ROE (%) -58.16
OXGN's ROE (%) is ranked higher than
66% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. OXGN: -58.16 )
OXGN' s 10-Year ROE (%) Range
Min: -8738.97   Max: -20.1
Current: -58.16

-8738.97
-20.1
ROA (%) -54.11
OXGN's ROA (%) is ranked higher than
63% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. OXGN: -54.11 )
OXGN' s 10-Year ROA (%) Range
Min: -224.41   Max: -15.51
Current: -54.11

-224.41
-15.51
ROC (Joel Greenblatt) (%) -46190.84
OXGN's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. OXGN: -46190.84 )
OXGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34348.94   Max: -250.74
Current: -46190.84

-34348.94
-250.74
EBITDA Growth (%) -62.50
OXGN's EBITDA Growth (%) is ranked higher than
51% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OXGN: -62.50 )
OXGN' s 10-Year EBITDA Growth (%) Range
Min: -66.2   Max: 24.3
Current: -62.5

-66.2
24.3
EPS Growth (%) -59.70
OXGN's EPS Growth (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OXGN: -59.70 )
OXGN' s 10-Year EPS Growth (%) Range
Min: -67.4   Max: 21.5
Current: -59.7

-67.4
21.5
» OXGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

OXGN Guru Trades in Q4 2012

John Keeley Sold Out
» More
Q2 2013

OXGN Guru Trades in Q2 2013

Jim Simons 17,585 sh (New)
» More
Q3 2013

OXGN Guru Trades in Q3 2013

Jim Simons 39,960 sh (+127.24%)
» More
Q4 2013

OXGN Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-12-31 Sold Out $0.34 - $5.29 $ 1.56206%0
John Keeley 2012-06-30 New Buy$0.62 - $1.1 $ 1.5671%28000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.03
OXGN's P/B is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. OXGN: 1.03 )
OXGN' s 10-Year P/B Range
Min: 0.24   Max: 12.17
Current: 1.03

0.24
12.17
EV-to-EBIT 0.05
OXGN's EV-to-EBIT is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OXGN: 0.05 )
OXGN' s 10-Year EV-to-EBIT Range
Min: -15.4   Max: 0.8
Current: 0.05

-15.4
0.8
Current Ratio 19.81
OXGN's Current Ratio is ranked higher than
95% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. OXGN: 19.81 )
OXGN' s 10-Year Current Ratio Range
Min: 0.81   Max: 58.71
Current: 19.81

0.81
58.71
Quick Ratio 19.81
OXGN's Quick Ratio is ranked higher than
95% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OXGN: 19.81 )
OXGN' s 10-Year Quick Ratio Range
Min: 0.81   Max: 58.71
Current: 19.81

0.81
58.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.03
OXGN's Price/Net Cash is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. OXGN: 1.03 )
OXGN' s 10-Year Price/Net Cash Range
Min: 0.88   Max: 347.97
Current: 1.03

0.88
347.97
Price/Net Current Asset Value 1.03
OXGN's Price/Net Current Asset Value is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. OXGN: 1.03 )
OXGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.88   Max: 347.97
Current: 1.03

0.88
347.97
Price/Tangible Book 1.03
OXGN's Price/Tangible Book is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. OXGN: 1.03 )
OXGN' s 10-Year Price/Tangible Book Range
Min: 0.83   Max: 18.18
Current: 1.03

0.83
18.18
Earnings Yield (Greenblatt) 2000.00
OXGN's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. OXGN: 2000.00 )
OXGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 120.9   Max: 13745.9
Current: 2000

120.9
13745.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:OXGP.Germany,
OxiGene, Inc. was incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware. The Company is a clinical-stage biopharmaceutical company that develops therapeutics to treat cancer and eye diseases. The Company primarily focuses on the development of vascular disrupting agents that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, and also are associated with visual impairment in a various ophthalmological diseases and conditions. Its principal product candidate includes ZYBRESTAT, a reversible tubulin binding agent for the treatment of anaplastic thyroid cancer, medullary thyroid cancer, Stage IV papillary thyroid cancer, Stage IV follicular thyroid cancer, carcinoid syndrome, and ovarian cancer. The company is also developing ZYBRESTAT for ophthalmological diseases and conditions that are characterized by abnormal blood vessel growth within the eye that result in loss of vision. In addition, it is developing OXi4503 for the treatment for certain solid tumor types and for the treatment of myeloid leukemias.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK